医学
西妥昔单抗
间质性肺病
内科学
表皮生长因子受体
肺癌
肿瘤科
头颈部鳞状细胞癌
头颈部癌
入射(几何)
不利影响
癌症
肺
结直肠癌
光学
物理
作者
Kenji Nakano,Akira Seto,Takahiko Sasaki,Wataru Shimbashi,Hirofumi Fukushima,Hiroyuki Yonekawa,Hiroki Mitani,Shunji Takahashi
出处
期刊:Head & neck
[Wiley]
日期:2019-03-04
卷期号:41 (8): 2574-2580
被引量:7
摘要
Interstitial lung disease (ILD) is known as a potentially severe adverse event associated with epidermal growth factor receptor (EGFR)-targeted therapy. The incidence and risk factors of ILD in patients with head and neck squamous cancer (HNSCC) treated with cetuximab, an anti-EGFR monoclonal antibody, have not been established.We retrospectively reviewed patients with HNSCC who received cetuximab from December 2012 to December 2016 at our institute and evaluated the incidence and risk factors of ILD.Of the 201 patients with HNSCC, ILD was observed in 9 patients (4.5%), 8 of whom had grade 3 or higher. High Krebs von den Lungen-6 (KL-6) and ≥50 pack-years of smoking were significantly predictive of associated with ILD (P = 0.00011 and 0.05, respectively).The incidence of ILD in patients with HNSCC treated with cetuximab was <5%, but most of the ILD cases were severe. High KL-6 and smoking histories might be predictive for ILD among patients with HNSCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI